Pharmaceutical company chooses Buchanan to invest in psychedelic medicine

0


The winning client is part of a larger partnership between commercial and financial relations agency and venture capital firms The Conscious Fund, which specializes in psychedelic medicine, drug discovery and addiction programs.

Corporate objectives

Announced today, Buchanan’s mandate for BetterLife is to support the life science company to achieve its business goals.

The aim is to increase its visibility with private and institutional investors, to build its reputation as a leader in the psychedelic medicine sector and to educate the public on the benefits of psychedelic treatments.

Buchanan won the account on a down payment basis as a result of its partnership with The Conscious Fund, which owns BetterLife Pharma among its portfolio of companies.

The account will be led by Henry Harrison-Topham, Partner and Head of the Cannabis & Wellness Team at Buchanan.

He said: “We are delighted to have been appointed as a Financial Communications Advisor by BetterLife Pharma, which is at the forefront of this exciting growth area. We look forward to sharing its investment proposal and growth prospects with generalist and specialist investors, while raising awareness in the wider market of the potential of psychedelic medicine. “

The psychedelic medicine industry is growing, with treatments aimed at people with addiction, depression and PTSD. But it is still a niche area and requires access to mainstream and financial media to stimulate investment and public understanding.

Ahmad Doroudian Ph.D, chief executive of BetterLife, said the company is entering “a phase of transformation” with “milestones” expected over the next six months.

He added: “We are very keen to expand our reach and share our story beyond the psychedelic sector, which is still quite niche today. We look forward to working with Buchanan, who has a proven track record in educating public and private capital markets through creative and impactful strategic communications.

Mainstream psychedelics

Buchanan, which is a WPP company, also announced its partnership with The Conscious Fund, which describes itself as a “startup investor in the psychedelic medicine industry.”

The agency said the partnership will combine its understanding of the impact of media on global and public financial markets with The Conscious Fund’s track record of investing in psychedelic medicine companies, in order to push the industry forward. ‘a niche area for traditional medicine.

Henri Sant-Cassia, Founding Partner of The Conscious Fund and Director of the BetterLife Pharma Board of Directors, said: “If psychedelic medicine is to reach its potential in the service of humanity, we must reach a wider and larger audience. generalist.

Harrison-Topham added, “We believe we are the ideal communications partner for this emerging industry due to our ability to convey a company’s investment proposition to public and private capital markets through creative strategic communications. and impactful. “


Click here to subscribe to the FREE Pharmaceuticals and Healthcare Newsletter to receive healthcare news, features and commentary straight to your inbox.

Be sure to register on the site to access more than one story per month.

To submit a news, commentary, case study or analysis idea for the Pharmaceutical and Health Communication Bulletin, email [email protected]


Leave A Reply

Your email address will not be published.